News and analysis for those planning for or living in retirement

[ad_1] From MarketWatch Retirement:  New Alzheimer’s drug shows some promise, but has big price tag. Lecanemab, which will be sold under the brand name Leqembi, will be priced at $26,500 per year. Leqembi has received a slightly warmer reception from the medical community than predecessor drug Aduhelm. What catch-up contribution? Congressional snafu leaves older retirement … Read more

Fundamental Analysis of Axis Bank

[ad_1] Fundamental Analysis of Axis Bank: Banks occupy a substantial portion of the overall stock market and they find their way into the portfolios of many investors. This can be either through mutual funds or by directly investing in stocks. However, analyzing banking stocks for the purpose of investment is slightly different from analyzing stocks … Read more